

Authorship of papers

For each trial there will be one or more identified main paper(s) signed by PENTA with an appendix with names of :

- the writing committee
- all committees related to the running of the trial
 - Steering Committee
 - Executive committee
 - DSMC
 - Immunology, virology, endpoint committees etc, where appropriate
- names of collaborators in all clinical centres enrolling children and providing follow-up
- staff at the co-ordinating centres involved in the trial

Other papers that come out of a trial should be signed by the person(s) who led the paper and who wrote it, followed by “on behalf of PENTA”. These should list names of the Steering Committee and any other committees or collaborators in clinical centres involved in the relevant substudy eg those centres which have performed pharmacokinetic studies for a PK substudy.

Before data or samples are released to any collaborator, he/she must agree to acknowledge PENTA in the authorship of any related papers or abstracts.

Where a clinical investigator uses data collected on his/her patients while they are enrolled in a PENTA trial, the publication must be cleared with the PENTA Steering Committee to ensure the publication does not impact on the trial. PENTA should also be acknowledged in any abstracts or papers.

Agreed by PENTA Steering Committee, June 2001